Current and future strategies for the treatment of malignant brain tumors.
about
Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma modelSelection of DNA aptamers against glioblastoma cells with high affinity and specificity.Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapyViral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expressionNovel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomasHuman gene therapy and imaging in neurological diseases.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionCombination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines.Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicineEffective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.Gene therapy and targeted toxins for glioma.Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes.Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours.Adenoviral-mediated gene transfer into the canine brain in vivo.Surgical management of high-grade gliomas.Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma.Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma.Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.Whole brain radiation-induced cognitive impairment: pathophysiological mechanisms and therapeutic targetsCharacterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor ProgressionThe origins of glioma: E Pluribus Unum?ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.Endothelial differentiation of adipose tissue-derived mesenchymal stromal cells in glioma tumors: implications for cell-based therapy.PEG2000-DPSE-coated quercetin nanoparticles remarkably enhanced anticancer effects through induced programed cell death on C6 glioma cells.Kaurene diterpene induces apoptosis in U87 human malignant glioblastoma cells by suppression of anti-apoptotic signals and activation of cysteine proteases.Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.Expression of activin A and follistatin in glioblastoma and their effects on U87 in vitro.Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.Radiobiological framework for the evaluation of stereotactic radiosurgery plans for invasive brain tumours.Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cellsEfficient gene therapy based targeting system for the treatment of inoperable tumors.
P2860
Q28476235-D3B8C7C1-F2E8-4108-A14E-2F21118C9F05Q28484184-29C50885-A967-486E-A3EB-D90B1B8C6FF6Q28485036-781289A0-09ED-4D30-9B30-3B320B9A4A8AQ30495981-444BB78D-46E0-4B00-B2DD-822E2064D736Q30542102-73403821-5631-4CA1-8CB9-22DD28FEE603Q31023442-DF47C767-533A-4343-B1BD-6CCBC3A68A60Q33551268-17CF5E65-A935-43D1-B20B-F492F4118FE3Q33642356-71136145-FA37-49B3-BB8E-CFBE8C53962DQ33853588-65C506BE-1CCD-42B5-945B-FEB9CBEFA22BQ34063140-BF717F92-1B22-4056-953B-FB160524F77FQ34546483-33643034-6597-4306-BF7F-97B33F4AAD00Q35034272-EED009CE-D9B4-42DB-9CCF-C067196492F6Q35069550-707C955C-695A-41ED-BB99-F174AC65A7EAQ35083593-3B0E7928-68A0-4036-AF51-F99952D09B1EQ35118919-62B267AC-9A8F-49BA-AE15-9C29B9E3D5FEQ35118933-F1C6D1C1-988B-455C-9AEA-2AF206AB6561Q35870480-BDBDCFAB-FC86-4918-9EFF-5CCCB1F12CFDQ35988225-61C0D762-405C-4091-84F7-1B2DD7069E05Q36150422-11990C3B-8113-49A6-88A0-9CF67219367AQ36172992-95BFB219-3689-4A96-94C1-810DF7F3DC50Q36307798-888DDAC8-2A3E-42DB-B812-9A6A781F53E2Q36499230-90C6EE98-090E-4372-BF45-E347919635BEQ36658322-288B154A-5CEC-4094-80C0-4DCE56658B01Q36952294-5B698751-AA00-4F50-B6AB-3DC62C448D38Q36994063-CCC705BB-659E-464E-AF7E-5BFEE615177CQ37145380-1531AFE5-3C03-4D49-99EC-6CD6EF767A22Q37344951-3CBC7E1E-711C-4C99-ACDA-AB611C90A348Q37693612-4F31EC8E-6032-4235-826A-9882FA293071Q37847107-7E1ADB24-8FEC-432F-9C76-5B0C7BCA6413Q38712677-59C6238A-70AD-4ED0-AF9A-508CCD95C4D7Q38824308-F44F6499-3C8C-471F-B367-A9C12F276976Q39140400-CA0F072D-62D4-45E9-AC77-5464800779DDQ39175576-1CD3E39B-B8AD-47F4-B081-068D4F1171EBQ39211543-E229276F-66A3-4F7C-8726-C6A40F337063Q39558094-53308D64-9A7E-4D3B-954D-35B25D6640C3Q39647689-18471B6F-4DA4-4BB2-B5CB-B0C1F6EE069EQ40213652-CF50D930-7675-4E84-9A0F-76FE763A69C2Q41875271-A243740F-82CD-405D-BD70-EBFA025CE24BQ41967160-152A054E-FB80-4455-B1C2-AB49869BC4D4Q45877862-41612FC8-BE15-4A42-95EF-A78DD7EF45E0
P2860
Current and future strategies for the treatment of malignant brain tumors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Current and future strategies for the treatment of malignant brain tumors.
@ast
Current and future strategies for the treatment of malignant brain tumors.
@en
type
label
Current and future strategies for the treatment of malignant brain tumors.
@ast
Current and future strategies for the treatment of malignant brain tumors.
@en
prefLabel
Current and future strategies for the treatment of malignant brain tumors.
@ast
Current and future strategies for the treatment of malignant brain tumors.
@en
P2093
P1476
Current and future strategies for the treatment of malignant brain tumors
@en
P2093
A Bigliari
I K Williamson
J C Williams
P R Lowenstein
P304
P356
10.1016/S0163-7258(03)00014-7
P577
2003-04-01T00:00:00Z